Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests apremilast to tame psoriasis Flare-Ups

NCT ID NCT07190391

First seen Sep 30, 2025 · Last updated May 25, 2026 · Updated 36 times

Summary

This study tests the drug apremilast in 425 adults with moderate-to-severe psoriasis that has lasted at least 6 months. The main goal is to see how many people achieve at least a 75% improvement in skin symptoms after 16 weeks. The study is open-label, meaning everyone knows they are getting the drug, and it lasts 32 weeks to check both effectiveness and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

Explore the condition pages connected to this study.